Answers are grounded in this paper and cite their sources.
Vaccine strategy enhances T-cell activation in murine models, suggesting a novel approach for cancer therapy.
Cancer vaccines have gained considerable attention for tumor prevention and therapy; however, their clinical efficacy remains limited by insufficient activation of antigen-specific cytotoxic T lymphocytes (CTLs). This limitation is primarily due to the inability of conventional vaccine components to effectively promote dendritic-cell-mediated cross-presentation and activation. While adjuvants are often used to enhance this interaction, many conventional adjuvants suffer from poor biocompatibility and systemic toxicity, limiting their clinical utility. Here, we report a vaccine strategy that leverages the bioorthogonal click chemistry reagent dibenzocyclooctyne (DBCO) as an adjuvant-like immune enhancer to promote cross-presentation and a CTL response. DBCO modification to antigen significantly increased antigen uptake by dendritic cells in vitro and promoted MHC class I-mediated cross-presentation via activation of the NF-κB/iNOS signaling pathway. In murine tumor models, systemic administration of DBCO-conjugated protein vaccines elicited enhanced CD8⁺ T-cell activation, leading to improved tumor control and long-term immune memory. Furthermore, DBCO-modified protein vaccines significantly suppressed tumor metastasis when combined with anti-PD-1 treatment. Collectively, our findings extend the immunotherapeutic potential of click chemistry reagents and establish a promising platform for enhancing CTL-mediated cancer vaccine efficacy in clinical settings.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: